Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer: Summary of the Dresden.

Slides:



Advertisements
Similar presentations
Image–Guided Radiation Therapy for Non–small Cell Lung Cancer
Advertisements

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Diffusion-weighted magnetic resonance imaging in preoperative assessment of non– small cell lung cancer  Hiroaki Nomori, MD, Yue Cong, MD, Masaru Abe,
Image–Guided Radiation Therapy for Non–small Cell Lung Cancer
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
Diffusion Magnetic Resonance Imaging in the Head and Neck
Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma  Anne.
The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer  Ramón Rami-Porta, MD, FETCS,
Electronic Updates for JTO Readers
Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer 
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Diffusion-Weighted Magnetic Resonance Imaging for Diagnosing Malignant Pulmonary Nodules/Masses: Comparison with Positron Emission Tomography  Takeshi.
Muhammad Umair Khawar, MD, Bhaskar Bhardwaj, MD, Himanshu Bhardwaj, MD 
A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib  Naoki Omachi, MD, Shigeki.
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non–Small Cell Lung Cancer Patient  Biagio Ricciuti,
Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.
Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,
Mediastinal Nodal Involvement in Patients with Clinical Stage I Non–Small-Cell Lung Cancer: Possibility of Rational Lymph Node Dissection  Tomohiro Haruki,
Dual-Energy Computed Tomography
A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib  Akihiro Tamiya,
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.
Nikolaas De Maeyer, MD, Walter De Wever, MD, PhD, Christophe M
Esophageal Ultrasound-Controlled Fine Needle Aspiration for Staging of Mediastinal Lymph Nodes in Patients with Resectable Lung Cancer: Do We Always See.
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
A Severe Photosensitivity Dermatitis Caused by Crizotinib
The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer  Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Jennifer.
Multiple Pulmonary Chondroid Hamartoma
MR-PET of the body: Early experience and insights
Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.
Evaluating Cryoablation of Metastatic Lung Tumors in Patients—Safety and Efficacy The ECLIPSE Trial—Interim Analysis at 1 Year  Thierry de Baere, MD,
Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib  Oana Pop, MD, Augustin Pirvu,
A new method for quantification of false lumen thrombosis in aortic dissection using magnetic resonance imaging and a blood pool contrast agent  Rachel.
Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature  Caicun Zhou, MD, PhD, Luan Di Yao, MD 
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib  Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,
The role of positron emission tomography for non-small cell lung cancer  Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD  Practical.
Thomas Henzler, MD, Ishar-Singh Gill, MD, Radko Krissak, MD, Stefan O
Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy  Naomi E. Verstegen,
Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller  Yangki Seok,
Early Stage Lung Cancer: Progress in the Last 40 Years
Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable.
Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L
Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS 
Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report 
Journal of Thoracic Oncology
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.
Kaustubh Limaye, MD, Ashutosh P. Jadhav, MD, PhD 
Tumor Response Kinetics after Schedule-Dependent Paclitaxel Chemoradiation Treatment for Inoperable Non-small Cell Lung Cancer: A Model for Low-Dose.
Multiple Primary Cancers or Multiple Metastases, That Is the Question
Multiple Pulmonary Nodules in an Elderly Woman
Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011)  Ellen.
Frequency and Prognostic Significance of Preoperatively Detected Enlarged Regional Lymph Nodes in Patients with Pathological Stage I Non-small Cell Lung.
Jie Huang, Juan Peng, Linlang Guo, MD, PhD 
Antiangiogenesis Induced Tumor Cavitation in Lung Cancer
Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD 
Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone?  Alvaro Leone, BSc.D 
International Thymic Malignancies Interest Group: A Way Forward
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Journal of Thoracic Oncology
Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma  Yu-Li Su, MD  Journal of Thoracic.
Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States  Megan E. Daly, MD, Julian R.
Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure  Joel P. Womack,
Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013  Chris Dickhoff, MD, Max Dahele, MBChB., PhD,
The IASLC Lung Cancer Staging Project
Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer  Chengwu.
Presentation transcript:

Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer: Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop  Thomas Henzler, MD, Peter Goldstraw, MD, Frederik Wenz, MD, Robert Pirker, MD, Walter Weder, MD, Paul Apfaltrer, MD, Mathias Meyer, MD, Karen Buesing, MD, Lucio Crino, MD, Dean Fennell, MD, PhD, Christian Fink, MD, Dominique Grunenwald, MD, Christian Manegold, MD, Lothar Pilz, MA, Stefan O. Schoenberg, MD, Senan Suresh, MD, Johan Vansteenkiste, MD, PhD, Wieland Voigt, MD, Björn Wängler, PhD, Gerald Schmid-Bindert, MD  Journal of Thoracic Oncology  Volume 10, Issue 2, Pages 237-249 (February 2015) DOI: 10.1097/JTO.0000000000000412 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 The figure demonstrates the principle of dual-energy CT. Dual-source CT systems are one way to acquire dual-energy CT datasets by operating the two X-ray tubes with two different tube voltages at the same time. Materials with high anatomic numbers like iodine show a different X-ray attenuation depending on the applied tube voltage (image on the left). The different tissue attenuation at different tube voltages allow to selectively visualize and quantify iodinated contrast material and thus blood within the tumor. CT, computed tomography. Journal of Thoracic Oncology 2015 10, 237-249DOI: (10.1097/JTO.0000000000000412) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 CT images of a 68-year-old patient with a central NSCLC that underwent whole tumor volume dynamic contrast-enhanced CT (A–D) as well as dual-energy CT for tumor staging before TKI therapy. A, One late arterial phase gray scale image 25 seconds after the contrast agent administration. B–D, Color-coded images representing blood volume (B), blood flow (C), and the mean transit time (D) of the contrast agent through the tumor. E and F, The corresponding dual-energy CT images. The blood volume (tissue iodine content) is color coded within the image and correlates with the blood volume from the dynamic series (B). The arrows demonstrate a highly perfused lymph node metastasis as well as a contralateral intrapulmonary metastasis. CT, computed tomography; NSCLC, non–small-cell lung cancer, TKI; tyrosine kinase inhibitor. Journal of Thoracic Oncology 2015 10, 237-249DOI: (10.1097/JTO.0000000000000412) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Left figure The basic principle of dynamic contrast-enhanced CT. Subsequently after the start of the intravenous administration of iodinated contrast material the anatomic region of interest is scanned several times with a very short so called inter-scan delay (usually 1.5–2.5 seconds in thoracic malignancies) between the different acquisitions. The measurement of the tissue contrast attenuation in all different acquisitions allows calculation of time intensity curves as well as calculation of multiple quantitative tissue parameters including blood volume, blood flow, tissue permeability, and the contrast agent mean transit time through the tissue. Right figure The advantage of whole tumor dynamic contrast-enhanced CT (lower row) that is not affected by tumor motion during different breathing cycles as well as inhomogeneous tumor tissue. Upper row Limitations of dynamic contrast-enhanced CT with older CT systems that limited the clinical value of the technique. CT, computed tomography. Journal of Thoracic Oncology 2015 10, 237-249DOI: (10.1097/JTO.0000000000000412) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 The figure demonstrates the principle of DWI with magnetic resonance imaging. Water molecules show a random Brownian movement in normal tissue leading to low signal intensity on DWI images. In cancer tissue with more cellularity and/or cellular edema, the Brownian movement is restricted which can be visualized on DWI images and quantified using the ADC. DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient. Journal of Thoracic Oncology 2015 10, 237-249DOI: (10.1097/JTO.0000000000000412) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions